Roivant Sciences Ltd. (ROIV): who owns it and who trades it
As of Nov 16, 2026, ROIV insiders reported 83 open-market sales worth $594M and no purchases in the last 12 months, with 25% of the sale value made under pre-set 10b5-1 plans. The largest seller was Keith S Manchester (Director), with $115M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Roivant Sciences
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ROIV
497 funds and institutions reported ROIV shares worth $20.6B at the end of Q2 2026, about 81% of the company. The largest holder is FMR LLC (Fidelity) with 11.3%.
Funds and institutions (13F) 81%Everyone else 19%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 81.02M | 11.26% | $2.9B | +4% |
| BlackRock, Inc. | 48.24M | 6.71% | $1.7B | +9% |
| Morgan Stanley | 42.59M | 5.92% | $1.5B | -18% |
| QVT Financial LP | 23.72M | 3.30% | $840M | -6% |
| Vanguard Capital Management LLC | 22.12M | 3.08% | $783M | +7% |
| Vanguard Portfolio Management LLC | 21.64M | 3.01% | $766M | +9% |
| California State Teachers Retirement System | 19.00M | 2.64% | $537M | +4212% |
| Goldman Sachs Group Inc | 18.56M | 2.58% | $657M | +67% |
| State Street Corp | 17.80M | 2.47% | $630M | +10% |
| UBS Group AG | 17.47M | 2.43% | $618M | -23% |
| Assenagon Asset Management S.A. | 16.73M | 2.33% | $592M | +136% |
| Farallon Capital Management, L.l.c. | 14.31M | 1.99% | $506M | +48% |
| Geode Capital Management, LLC | 11.67M | 1.62% | $426M | +15% |
| Adage Capital Partners Gp, L.l.c. | 10.35M | 1.44% | $366M | -19% |
| Two Seas Capital LP | 8.48M | 1.18% | $300M | -9% |
| Perceptive Advisors LLC | 8.09M | 1.12% | $286M | -2% |
| Patient Square Capital LP | 8.02M | 1.12% | $284M | -2% |
| Invesco Ltd. | 7.53M | 1.05% | $267M | +17% |
| Darwin Global Management, Ltd. | 6.75M | 0.94% | $234M | -1% |
| AQR Capital Management LLC | 6.63M | 0.92% | $234M | +12% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ROIV insiders reported $0 of open-market purchases and $594M of sales. 25% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Richard Pulik | CFO | Sale | 45,195 | $41.47 | $1.9M | Form 4 |
| Nov 11, 2026 | Richard Pulik | CFO | Sale | 82,170 | $42.03 | $3.5M | Form 4 |
| Nov 11, 2026 | Richard Pulik | CFO | Sale | 47,635 | $41.89 | $2M | Form 4 |
| Nov 10, 2026 | Richard Pulik | CFO | Sale | 125,000 | $41.20 | $5.2M | Form 4 |
| Nov 10, 2026 | Eric Venker | CEO | Sale plan | 158,194 | $40.44 | $6.4M | Form 4 |
| Nov 10, 2026 | Eric Venker | CEO | Sale plan | 29,749 | $41.00 | $1.2M | Form 4 |
| Nov 3, 2026 | Eric Venker | CEO | Sale plan | 200,000 | $36.31 | $7.3M | Form 4 |
| Oct 28, 2026 | Eric Venker | CEO | Sale plan | 200,000 | $36.59 | $7.3M | Form 4 |
| Oct 20, 2026 | Eric Venker | CEO | Sale plan | 185,856 | $35.09 | $6.5M | Form 4 |
| Oct 20, 2026 | Eric Venker | CEO | Sale plan | 14,144 | $35.42 | $501K | Form 4 |
| Oct 1, 2026 | Melissa B Epperly | Director | Sale plan | 16,850 | $36.08 | $608K | Form 4 |
| Oct 1, 2026 | Melissa B Epperly | Director | Sale plan | 900 | $36.57 | $32.9K | Form 4 |
| Sep 30, 2026 | Eric Venker | CEO | Sale plan | 200,000 | $36.62 | $7.3M | Form 4 |
| Sep 15, 2026 | Melissa B Epperly | Director | Sale plan | 4,338 | $39.65 | $172K | Form 4 |
| Sep 15, 2026 | Melissa B Epperly | Director | Sale plan | 600 | $40.38 | $24.2K | Form 4 |
| Sep 15, 2026 | Meghan Fitzgerald | Director | Sale plan | 400 | $40.45 | $16.2K | Form 4 |
| Sep 15, 2026 | Meghan Fitzgerald | Director | Sale plan | 4,712 | $39.68 | $187K | Form 4 |
| Sep 8, 2026 | Meghan Fitzgerald | Director | Sale | 20,000 | $39.90 | $798K | Form 4 |
| Aug 28, 2026 | Eric Venker | CEO | Sale | 166,182 | $35.63 | $5.9M | Form 4 |
| Aug 28, 2026 | Eric Venker | CEO | Sale | 33,818 | $36.44 | $1.2M | Form 4 |
| Aug 21, 2026 | Mayukh Sukhatme | President | Sale | 144,756 | $36.48 | $5.3M | Form 4 |
| Aug 20, 2026 | Mayukh Sukhatme | President | Sale | 17,519 | $37.30 | $653K | Form 4 |
| Aug 19, 2026 | Mayukh Sukhatme | President | Sale | 172,899 | $37.17 | $6.4M | Form 4 |
| Aug 18, 2026 | Mayukh Sukhatme | President | Sale | 105,141 | $36.59 | $3.8M | Form 4 |
| Aug 18, 2026 | Mayukh Sukhatme | President | Sale | 31,801 | $37.18 | $1.2M | Form 4 |
| Aug 17, 2026 | Mayukh Sukhatme | President | Sale | 284,707 | $36.25 | $10.3M | Form 4 |
| Aug 14, 2026 | Mayukh Sukhatme | President | Sale | 243,177 | $36.23 | $8.8M | Form 4 |
| Jul 27, 2026 | Eric Venker | CEO | Sale | 200,000 | $34.95 | $7M | Form 4 |
| Jun 30, 2026 | Meghan Fitzgerald | Director | Sale plan | 10,000 | $34.90 | $349K | Form 4 |
| Jun 30, 2026 | Keith S Manchester | Director | Sale | 200,000 | $35.45 | $7.1M | Form 4 |
| Jun 30, 2026 | Keith S Manchester | Director | Sale | 12,380 | $35.28 | $437K | Form 4 |
| Jun 29, 2026 | Melissa B Epperly | Director | Sale plan | 2,748 | $34.71 | $95.4K | Form 4 |
| Jun 29, 2026 | Melissa B Epperly | Director | Sale plan | 15,002 | $34.32 | $515K | Form 4 |
| Jun 29, 2026 | Keith S Manchester | Director | Sale | 600,000 | $34.59 | $20.8M | Form 4 |
| Jun 29, 2026 | Keith S Manchester | Director | Sale | 200,000 | $34.44 | $6.9M | Form 4 |
| Jun 26, 2026 | Keith S Manchester | Director | Sale | 325,000 | $34.07 | $11.1M | Form 4 |
| Jun 26, 2026 | Keith S Manchester | Director | Sale | 300,783 | $33.92 | $10.2M | Form 4 |
| Jun 26, 2026 | Mayukh Sukhatme | President | Sale | 500,000 | $34.08 | $17M | Form 4 |
| Jun 25, 2026 | Mayukh Sukhatme | President | Sale | 500,000 | $34.13 | $17.1M | Form 4 |
| Jun 24, 2026 | Eric Venker | CEO | Sale plan | 46,234 | $33.51 | $1.5M | Form 4 |
| Jun 24, 2026 | Eric Venker | CEO | Sale plan | 153,766 | $33.05 | $5.1M | Form 4 |
| May 22, 2026 | Eric Venker | CEO | Sale plan | 200,000 | $30.27 | $6.1M | Form 4 |
| Apr 20, 2026 | Eric Venker | CEO | Sale plan | 200,000 | $29.59 | $5.9M | Form 4 |
| Apr 16, 2026 | Matthew Gline | CEO | Sale | 289,774 | $29.16 | $8.4M | Form 4 |
| Apr 8, 2026 | Jennifer Humes | Chief Accounting Officer | Sale | 13,538 | $28.37 | $384K | Form 4 |
| Mar 26, 2026 | Meghan Fitzgerald | Director | Sale | 70,000 | $27.45 | $1.9M | Form 4 |
| Mar 17, 2026 | Eric Venker | CEO | Sale plan | 200,000 | $28.24 | $5.6M | Form 4 |
| Mar 16, 2026 | Melissa B Epperly | Director | Sale | 41,861 | $28.68 | $1.2M | Form 4 |
| Feb 23, 2026 | Frank Torti | President | Sale plan | 587,390 | $27.51 | $16.2M | Form 4 |
| Feb 20, 2026 | Frank Torti | President | Sale plan | 1.01M | $27.15 | $27.5M | Form 4 |
| Feb 19, 2026 | Frank Torti | President | Sale plan | 1.40M | $27.42 | $38.4M | Form 4 |
| Feb 13, 2026 | Eric Venker | CEO | Sale plan | 200,000 | $26.49 | $5.3M | Form 4 |
| Feb 13, 2026 | Keith S Manchester | Director | Sale | 150,784 | $26.49 | $4M | Form 4 |
| Feb 13, 2026 | Keith S Manchester | Director | Sale | 225,000 | $26.50 | $6M | Form 4 |
| Feb 12, 2026 | Keith S Manchester | Director | Sale | 275,000 | $26.76 | $7.4M | Form 4 |
| Feb 12, 2026 | Keith S Manchester | Director | Sale | 150,000 | $26.72 | $4M | Form 4 |
| Feb 11, 2026 | Keith S Manchester | Director | Sale | 425,000 | $26.67 | $11.3M | Form 4 |
| Feb 9, 2026 | Mayukh Sukhatme | President | Sale | 339,441 | $26.47 | $9M | Form 4 |
| Jan 12, 2026 | Eric Venker | CEO | Sale | 200,000 | $21.92 | $4.4M | Form 4 |
| Dec 31, 2025 | Mayukh Sukhatme | President | Sale | 1.02M | $21.71 | $22.1M | Form 4 |
| Dec 29, 2025 | Mayukh Sukhatme | President | Sale | 311,873 | $21.74 | $6.8M | Form 4 |
| Dec 24, 2025 | Eric Venker | CEO | Sale | 75,000 | $22.53 | $1.7M | Form 4 |
| Dec 23, 2025 | Richard Pulik | CFO | Sale | 146,731 | $22.39 | $3.3M | Form 4 |
| Dec 23, 2025 | Richard Pulik | CFO | Sale | 260,000 | $22.45 | $5.8M | Form 4 |
| Dec 23, 2025 | Eric Venker | CEO | Sale | 200,000 | $22.45 | $4.5M | Form 4 |
| Dec 17, 2025 | Mayukh Sukhatme | President | Sale | 26,831 | $23.09 | $620K | Form 4 |
| Dec 17, 2025 | Daniel Allen Gold | Director | Sale | 189,538 | $23.17 | $4.4M | Form 4 |
| Dec 17, 2025 | Daniel Allen Gold | Director | Sale | 155,076 | $23.02 | $3.6M | Form 4 |
| Dec 17, 2025 | Daniel Allen Gold | Director | Sale | 432,718 | $23.05 | $10M | Form 4 |
| Dec 16, 2025 | Daniel Allen Gold | Director | Sale | 642,282 | $23.08 | $14.8M | Form 4 |
| Dec 16, 2025 | Daniel Allen Gold | Director | Sale | 275,000 | $22.93 | $6.3M | Form 4 |
| Dec 15, 2025 | Matthew Gline | CEO | Sale | 943,527 | $21.68 | $20.5M | Form 4 |
| Dec 15, 2025 | Matthew Gline | CEO | Sale | 230,357 | $21.68 | $5M | Form 4 |
| Dec 15, 2025 | Matthew Gline | CEO | Sale | 566,116 | $21.68 | $12.3M | Form 4 |
| Dec 15, 2025 | Vivek Ramaswamy | 10% owner | Sale | 353,745 | $22.05 | $7.8M | Form 4 |
| Dec 12, 2025 | Vivek Ramaswamy | 10% owner | Sale | 1.98M | $21.96 | $43.4M | Form 4 |
| Dec 11, 2025 | Vivek Ramaswamy | 10% owner | Sale | 774,142 | $21.64 | $16.8M | Form 4 |
| Dec 9, 2025 | Eric Venker | CEO | Sale | 200,000 | $20.85 | $4.2M | Form 4 |
| Nov 19, 2025 | Keith S Manchester | Director | Sale | 850,000 | $20.25 | $17.2M | Form 4 |
| Nov 19, 2025 | Keith S Manchester | Director | Sale | 150,000 | $20.20 | $3M | Form 4 |
| Nov 19, 2025 | Keith S Manchester | Director | Sale | 125,000 | $20.16 | $2.5M | Form 4 |
| Nov 19, 2025 | Keith S Manchester | Director | Sale | 175,000 | $20.24 | $3.5M | Form 4 |
| Nov 17, 2025 | Vivek Ramaswamy | 10% owner | Sale | 539,650 | $20.51 | $11.1M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Keith S Manchester | Director | – | $115M | Jun 30, 2026 |
| Mayukh Sukhatme | President & CIO, Director | – | $109M | Aug 21, 2026 |
| Eric Venker | President & Immunovant CEO | – | $95M | Nov 10, 2026 |
| Frank Torti | President and Vant Chair | – | $82M | Feb 23, 2026 |
| Vivek Ramaswamy | 10% owner | – | $79M | Dec 15, 2025 |
| Matthew Gline | CEO, Director | – | $46.2M | Apr 16, 2026 |
| Daniel Allen Gold | Director | – | $39.1M | Dec 17, 2025 |
| Richard Pulik | CFO | – | $21.6M | Nov 11, 2026 |
| Meghan Fitzgerald | Director | – | $3.3M | Sep 15, 2026 |
| Melissa B Epperly | Director | – | $2.6M | Oct 1, 2026 |
| Jennifer Humes | Chief Accounting Officer | – | $384K | Apr 8, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ROIV short interest
Moderate short interest. 6.3% of ROIV shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went up 66%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 45.51M ROIV shares were sold short, 6.3% of the shares outstanding, up 12.9% from the report before. At the average daily volume of 7.50M shares, buying them all back would take about 6.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 45.51M | 6.30% | +13% | 7.50M | 6.1 |
| Oct 15, 2026 | 40.30M | 5.58% | +3% | 5.11M | 7.9 |
| Sep 30, 2026 | 39.30M | 5.44% | +9% | 8.88M | 4.4 |
| Sep 15, 2026 | 36.18M | 5.01% | +8% | 8.75M | 4.1 |
| Aug 31, 2026 | 33.52M | 4.64% | +10% | 8.76M | 3.8 |
| Aug 14, 2026 | 30.60M | 4.24% | -13% | 6.10M | 5.0 |
| Jul 31, 2026 | 35.23M | 4.88% | -4% | 4.41M | 8.0 |
| Jul 15, 2026 | 36.70M | 5.10% | +10% | 4.80M | 7.7 |
| Jun 30, 2026 | 33.21M | 4.62% | -0% | 7.78M | 4.3 |
| Jun 15, 2026 | 33.24M | 4.62% | -8% | 4.42M | 7.5 |
| May 29, 2026 | 36.23M | 5.04% | +32% | 8.75M | 4.1 |
| May 15, 2026 | 27.38M | 3.81% | +1% | 4.81M | 5.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded ROIV
Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 2 sales of ROIV. The latest was a sale by Lisa C. McClain on Oct 31, 2025, reported Nov 21, 2025.
Purchases 2Sales 2
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Oct 31, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Oct 30, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Nov 21, 2025 | Report |
| Jun 17, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Roivant Sciences company events
Roivant Sciences filed 14 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 21, 2026AnnouncementShared information with investors. Filing
- Sep 18, 2026VoteReported shareholder vote results. Filing
- Sep 8, 2026AnnouncementShared information with investors. Filing
- Aug 28, 2026AnnouncementRoivant Sciences Ltd. posted a presentation regarding the approval by the U.S. Food and Drug Administration of LISRAYA™ (brepocitinib) for the treatment of adults with dermatomyositis on the “Events & Presentations” page of its investor relations website at investor.roivant.com. Filing
- Aug 27, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 20, 2026ResultsReleased financial results. Filing
- Apr 2, 2026ResultsReleased financial results. Filing
- Mar 23, 2026AgreementAmended an earlier report. Of the Original 8-K, which indicated that a copy of the Settlement Agreement would be filed as an exhibit to a subsequent filing with the SEC. Except as set forth herein, no other changes have been made to the Original 8-K, and this Amendment does not modify or update any other disclosures set… Filing
- Mar 3, 2026AgreementGenevant Sciences GmbH, a subsidiary of Roivant Sciences Ltd., Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement to resolve… Filing
- Mar 3, 2026AnnouncementShared information with investors. Filing
- Feb 6, 2026ResultsReleased financial results. Filing
- Dec 11, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Roivant Sciences financials
Famous investors that hold ROIV
6 of the 50 well-known investors we track reported holding ROIV in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $247M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Andreas Halvorsen · Viking Global Investors | Q3 2026 | 6.76M | $247M | 0.8% | +8% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 4.82M | $176M | 0.3% | +8% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 2.31M | $84.4M | 0.7% | -18% |
| David Einhorn · Greenlight Capital (DME) | Q3 2026 | 1.13M | $41.4M | 1.2% | -47% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 962,603 | $35.2M | 0.0% | -83% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 13,597 | $497K | 0.0% | -14% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ROIV in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 5, 2026 | FMR LLC | 13G/A | 11.8% |
| Nov 5, 2026 | FMR LLC | 13G/A | 11.8% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 8.2% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 8.2% |
Questions about Roivant Sciences Ltd. (ROIV) stock
Who owns the most ROIV stock?
The largest reported owner of Roivant Sciences Ltd. (ROIV) is FMR LLC (Fidelity), with 11.3% of the company. In total, 497 funds and institutions reported holding ROIV at the end of Q2 2026, together about 81% of the shares. See the largest owners.
Are ROIV insiders buying or selling?
In the last 12 months, ROIV insiders reported no open-market purchases and 83 sales worth $594M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in ROIV?
As of Oct 30, 2026, 45.51M ROIV shares were sold short, 6.3% of the shares outstanding, up 12.9% from the report before. At the average daily volume of 7.50M shares, buying them all back would take about 6.1 trading days (days to cover). See the history.
Have members of Congress traded ROIV?
Yes. 1 member of Congress reported 2 purchases and 2 sales of ROIV since Nov 17, 2024. The latest was reported on Nov 21, 2025. See the trades.
Which famous investors hold ROIV?
6 of the 50 well-known investors we track reported ROIV in their latest 13F filing, including Andreas Halvorsen, Steve Cohen, Lee Ainslie. The largest position is worth $247M. See all holders.
Executive pay
Roivant Sciences's chief executive was paid a total of $3.1M for the year ended Mar 31, 2026, down 98% from $163M the year before. In the last 12 months, Roivant Sciences's executives and directors bought no stock on the open market and sold $515M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.